Empower Clinics Announces Closing of $2.1 Million Private Placement

Rhea-AI Summary

Empower Clinics Inc. has successfully closed a non-brokered private placement of unsecured convertible debenture units, raising a total of $2,100,000. Each Unit consists of a 6.0% senior unsecured convertible debenture priced at $1,000 and includes 5,000 common share purchase warrants. The funds will be allocated to growth plans, working capital, and general administrative expenses. Notably, the Company issued fees amounting to $197,000 and provided additional securities to a finder. All issued securities are subject to a hold period of four months.

Positive

• Raised $2,100,000 through private placement.
• Conversion option for debentures at $0.20 per share benefits investors.

Negative

• Cash fees and securities issued to finders total to $197,000 and 2,100,000 warrants, potentially diluting shareholder value.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESSWIRE / March 28, 2022 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) ("Empower" or the "Company") is pleased to announce that it has closed a non-brokered private placement of unsecured convertible debenture units (each a "Unit") at a price of $1,000 per Unit for aggregate gross proceeds of $2,100,000 (the "Financing").

Each Unit consisted of one 6.0% senior unsecured convertible debenture of the Company having a principal amount of $1,000 (each, a "Debenture") and 5,000 common share purchase warrants, each of which is exercisable into one common share in the capital of the Company (each, a "Share") at a price of $0.30 per share until March 25, 2024. The Debentures will bear interest at the rate of 6.0% per annum and mature on March 25, 2024. The principal amount of each Debenture shall be convertible, for no additional consideration, into Shares at the option of the holder at any time prior to the maturity date at a conversion price of $0.20 per Share, subject to customary adjustments.

"Our Company, our path and the healthcare foundation we are building, is in great shape." Said Steven McAuley CEO and Chair of the Board of Empower. "We have evolved through these changing times, and we embrace our change. We embark, with legacy assets departed, and an abundance of opportunities in our journey ahead."

The Company intends to use the net proceeds raised under the Financing to advance its growth plans, and for working capital purposes and general administrative expenses.

In connection with the Financing, the Company paid cash fees of $197,000 and issued a finder 210,000 Shares and 1,890,000 warrants, each of which is exercisable into one Share at a price of $0.30 per Share until March 25, 2024.

All securities issued pursuant to the Financing are subject to a hold period of four months and one day under applicable Canadian securities laws.

ABOUT EMPOWER

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, a medical device company and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Its Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Media:

Steven McAuley CEO
s.mcauley@empowerclinics.com
604-227-0865

Investors:

Tamara Mason
Business Development &
Communications
t.mason@empowerclinics.com
604-359-9107

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding the expected use of proceeds of the Financing. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including that the Company may determine it is in the best interest of the Company to use the Financing proceeds for reasons other than those set out in this release, and other factors beyond the Company's control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

SOURCE: Empower Clinics Inc.

View source version on accesswire.com:
https://www.accesswire.com/694854/Empower-Clinics-Announces-Closing-of-21-Million-Private-Placement

FAQ

What was the total amount raised by Empower Clinics in the recent financing?

Empower Clinics raised a total of $2,100,000 through a non-brokered private placement.

What are the terms of the convertible debentures issued by Empower Clinics?

The convertible debentures have a principal amount of $1,000, an interest rate of 6.0%, and a maturity date of March 25, 2024.

What is the conversion price for the debentures into common shares of Empower Clinics?

The conversion price is set at $0.20 per share.

How will Empower Clinics use the proceeds from the financing?

The proceeds will be used for growth plans, working capital, and general administrative expenses.

Are there any hold periods for the securities issued under the financing?

Yes, all securities issued are subject to a hold period of four months and one day.